84 research outputs found
Π‘ΠΠΠ ΠΠΠΠΠΠ«Π ΠΠ‘ΠΠΠΠ’Π« Π‘Π’ΠΠΠΠΠ Π’ΠΠΠΠ¦ΠΠ ΠΠΠΠΠΠΠΠ’ΠΠ§ΠΠ‘ΠΠΠ₯ ΠΠΠΠΠ Π‘Π’ΠΠΠΠΠ«Π₯ ΠΠ ΠΠΠΠ ΠΠ’ΠΠ
The article describes the status of homeopathic medicines standardisation in the leading world pharmacopoeias. It reviews main requirements for raw materials of plant, animal, and mineral origin, which are used in the production of homeopathic medicines. It also considers requirements for homeopathic pharmaceutical substances, including technologies of obtaining homeopathic mother tinctures, homeopathic dilutions, triturations, etc., mono- and multi-component homeopathic medicines, as well as quality control of homeopathic substances and homeopathic medicines. The article analyses the nomenclature of homeopathic raw materials and homeopathic substances used by the leading world pharmacopoeias. It dwells upon the results of work devoted to the development of requirements for the following homeopathic dosage forms: homeopathic granules, homeopathic eye drops, homeopathic ointments, homeopathic infusions and decoctions,Β homeopathic mother tinctures,Β homeopathic solutions for injection,Β homeopathic solutions and liquid dilutions,Β homeopathic syrups, homeopathic mixtures,Β homeopathic suppositories, homeopathic tablets, homeopathic triturations.Β The article illustrates significant potential of using vibrational spectroscopy and Raman spectroscopy for the detection of distinctive features of homeopathic medicines at ultra-high dilutions. The article presents methodology for structuring pharmacopoeial standards for raw materials used in the production of pharmaceutical substances, for pharmaceutical substances that are used in homeopathic medicines, and for dosage forms, including specific aspects of production and standardisation of homeopathic medicines, which was implemented during preparation of draft monographs for the State Pharmacopoeia of the Russian Federation.ΠΡ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°Π½ΠΎ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΠΈΠΈ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ² Π² Π²Π΅Π΄ΡΡΠΈΡ
Π·Π°ΡΡΠ±Π΅ΠΆΠ½ΡΡ
ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΏΠ΅ΡΡ
. Π Π°ΡΡΠΌΠΎΡΡΠ΅Π½Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΠ΅Β ΡΡΠ΅Π±ΠΎΠ²Π°Π½ΠΈΡΒ ΠΊ ΡΡΡΡΡ ΡΠ°ΡΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ, ΠΆΠΈΠ²ΠΎΡΠ½ΠΎΠ³ΠΎ ΠΈ ΠΌΠΈΠ½Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠΈΡΡ
ΠΎΠΆΠ΄Π΅Π½ΠΈΡ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΠΎΠ³ΠΎ Π΄Π»Ρ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡΒ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ². Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Ρ ΡΡΠ΅Π±ΠΎΠ²Π°Π½ΠΈΡΒ ΠΊ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΡΠΌ, Π² ΡΠΎΠΌ ΡΠΈΡΠ»Π΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈΒ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡΒ Π½Π°ΡΡΠΎΠ΅ΠΊΒ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΡΠΈΡΠ½ΡΡ
,Β Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Β ΡΠ°Π·Π²Π΅Π΄Π΅Π½ΠΈΠΉ, ΡΡΠΈΡΡΡΠ°ΡΠΈΠΉΒ ΠΈ Π΄Ρ., ΠΌΠΎΠ½ΠΎ-Β ΠΈ ΠΌΠ½ΠΎΠ³ΠΎΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ½ΡΡ
Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², Π° ΡΠ°ΠΊΠΆΠ΅ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΒ Β ΠΊΠ°ΡΠ΅ΡΡΠ²Π°Β Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΉΒ Β ΠΈΒ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ².Β ΠΡΠΈΠ²Π΅Π΄Π΅Π½Β Β Π°Π½Π°Π»ΠΈΠ· Π½ΠΎΠΌΠ΅Π½ΠΊΠ»Π°ΡΡΡΡ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΡΡΡΡΒ ΠΈ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΉΒ ΠΏΠΎ Π²Π΅Π΄ΡΡΠΈΠΌΒ Π·Π°ΡΡΠ±Π΅ΠΆΠ½ΡΠΌ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΏΠ΅ΡΠΌ. ΠΡΡΠ°Π±ΠΎΡΠ°Π½ΡΒ ΡΡΠ΅Π±ΠΎΠ²Π°Π½ΠΈΡ, ΠΏΡΠ΅Π΄ΡΡΠ²Π»ΡΠ΅ΠΌΡΠ΅ ΠΊ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠΌ ΡΠΎΡΠΌΠ°ΠΌ: Β«ΠΡΠ°Π½ΡΠ»Ρ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅Β», Β«ΠΠ°ΠΏΠ»ΠΈ Π³Π»Π°Π·Π½ΡΠ΅ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅Β», Β«ΠΠ°Π·ΠΈ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅Β», Β«ΠΠ°ΡΡΠΎΠΈ ΠΈ ΠΎΡΠ²Π°ΡΡ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅Β», Β«ΠΠ°ΡΡΠΎΠΉΠΊΠΈ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΌΠ°ΡΡΠΈΡΠ½ΡΠ΅Β», Β«Π Π°ΡΡΠ²ΠΎΡΡ Π΄Π»Ρ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΉ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅Β», Β«Π Π°ΡΡΠ²ΠΎΡΡ ΠΈ ΠΆΠΈΠ΄ΠΊΠΈΠ΅ ΡΠ°Π·Π²Π΅Π΄Π΅Π½ΠΈΡΒ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅Β», Β«Π‘ΠΈΡΠΎΠΏΡ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅Β», Β«Π‘ΠΌΠ΅ΡΠΈ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅Β», Β«Π‘ΡΠΏΠΏΠΎΠ·ΠΈΡΠΎΡΠΈΠΈ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅Β», Β«Π’Π°Π±Π»Π΅ΡΠΊΠΈ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅Β», Β«Π’ΡΠΈΡΡΡΠ°ΡΠΈΠΈ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅Β». ΠΠΎΠΊΠ°Π·Π°Π½Π° ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ² Π²ΠΈΠ±ΡΠ°ΡΠΈΠΎΠ½Π½ΠΎΠΉ ΠΈ ΡΠ°ΠΌΠ°Π½ΠΎΠ²ΡΠΊΠΎΠΉ ΡΠΏΠ΅ΠΊΡΡΠΎΡΠΊΠΎΠΏΠΈΠΈ Π΄Π»Ρ Π²ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΎΡΠ»ΠΈΡΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ²Β ΠΏΡΠΈ ΡΠ²Π΅ΡΡ
Π²ΡΡΠΎΠΊΠΎΠΌΒ ΡΠ°Π·Π²Π΅Π΄Π΅Π½ΠΈΠΈ. Π Π°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π° ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΡΒ ΠΏΠΎΡΡΡΠΎΠ΅Π½ΠΈΡ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΏΠ΅ΠΉΠ½ΡΡ
ΡΡΠ°Π½Π΄Π°ΡΡΠΎΠ²Β Π½Π° ΡΡΡΡΠ΅Β Π΄Π»Ρ ΠΏΡΠΎΠΈΠ·Π²ΠΎΠ΄ΡΡΠ²Π° ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΉ, ΡΠ°ΡΠΌΠ°ΡΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΡΠ±ΡΡΠ°Π½ΡΠΈΠΈ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΠ΅ Π΄Π»Ρ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡΒ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
Β ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ², ΠΈ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠ΅ ΡΠΎΡΠΌΡ,Β Π²ΠΊΠ»ΡΡΠ°ΡΡΠΈΠ΅Β ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈΒ ΠΈ ΡΡΠ°Π½Π΄Π°ΡΡΠΈΠ·Π°ΡΠΈΠΈ Π³ΠΎΠΌΠ΅ΠΎΠΏΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΡ
ΡΡΠ΅Π΄ΡΡΠ², ΡΠ΅Π°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½ΡΠ΅ ΠΏΡΠΈ ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠ΅Β ΠΏΡΠΎΠ΅ΠΊΡΠΎΠ²Β ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΏΠ΅ΠΉΠ½ΡΡ
ΡΡΠ°ΡΠ΅ΠΉ Π΄Π»Ρ ΠΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠ°ΡΠΌΠ°ΠΊΠΎΠΏΠ΅ΠΈ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ
Effect of simvastatin on fatty acids composition of erythrocyte membranes in women with chronic form of coronary heart disease
23 women with a chronic form of coronary heart disease (CHD) were examined before and after two months of taking simvastatin at doses of 40 and 80 mg/day. Regardless of the dosage the reduction in total cholesterol (TC) level, low-density lipoprotein cholesterol (LDL-C) and atherogenic index (Al) was found that pointed at the strengthening of receptor-mediated endocytosis in LDL-C cells with all portable fatty acids (FA) in them by apoB-100 cells, in various forms of esters. The spectrum of FA in the erythrocyte membrane phospholipids (FL) was researched by gas-liquid chromatography-mass spectrometry. Redistribution of FA was revealed after treatment with different doses: reduction of the unsaturation index (UI) of the membranes erythrocytes indicated a violation of physical, chemical and functional properties of cell membranes. The content of the FA-membrane substrates and substrates of vitamin F, triglycerol substrates (TGL) decreased and FA-energy substrates cells increased. Probably, the ability of statins to activate the desaturase enzymes had an effect of the increasing of long-chain Ο-9 FA content. In this case the reduction of oleic Ο-9 FA influenced the reduction of TGL. Unlike doses of 40 mg/day treatment at a dosage of 80 mg/day in women resulted the increase of relation Ο-3/Ο-6 LC and the decrease of dihomo-Ξ³-linolenic LCD. It indicated the formation of favorable conditions of the normalization of cell function in vivo. Under these conditions the level of palmitic FA and, correspondingly, the activity of atheromatosis decreased
MODERN ASPECTS OF HOMEOPATHIC MEDICINES STANDARDISATION
The article describes the status of homeopathic medicines standardisation in the leading world pharmacopoeias. It reviews main requirements for raw materials of plant, animal, and mineral origin, which are used in the production of homeopathic medicines. It also considers requirements for homeopathic pharmaceutical substances, including technologies of obtaining homeopathic mother tinctures, homeopathic dilutions, triturations, etc., mono- and multi-component homeopathic medicines, as well as quality control of homeopathic substances and homeopathic medicines. The article analyses the nomenclature of homeopathic raw materials and homeopathic substances used by the leading world pharmacopoeias. It dwells upon the results of work devoted to the development of requirements for the following homeopathic dosage forms: homeopathic granules, homeopathic eye drops, homeopathic ointments, homeopathic infusions and decoctions,Β homeopathic mother tinctures,Β homeopathic solutions for injection,Β homeopathic solutions and liquid dilutions,Β homeopathic syrups, homeopathic mixtures,Β homeopathic suppositories, homeopathic tablets, homeopathic triturations.Β The article illustrates significant potential of using vibrational spectroscopy and Raman spectroscopy for the detection of distinctive features of homeopathic medicines at ultra-high dilutions. The article presents methodology for structuring pharmacopoeial standards for raw materials used in the production of pharmaceutical substances, for pharmaceutical substances that are used in homeopathic medicines, and for dosage forms, including specific aspects of production and standardisation of homeopathic medicines, which was implemented during preparation of draft monographs for the State Pharmacopoeia of the Russian Federation
Forced-ferromagnetic state in a Tm2Fe17H5 single crystal
International audienceWe report the attainment of the ferromagnetic state in an interstitially modified heavy rare-earth-iron intermetallic compound in an external magnetic field. The starting composition is RE2Fe17, which is the RE-Fe binary richest in iron. We concentrate on the Tm-Fe compound, which is the most sensitive to magnetic field. The maximum possible amount of hydrogen (5 at. H/f.u.) is inserted into a Tm2Fe17 single crystal. We demonstrate that in a magnetic field of 57 T Tm2Fe17H5 reaches the ferromagnetic state with an enviably high polarization of 2.25 T
57Fe MΓΆssbauer effect studies of ErFe11Ti and ErFe11TiH compounds
Ferromagnetic compounds ErFe11TiHx (x = 0, 1) have been investigated by 57Fe MΓΆssbauer spectroscopy in the temperature range 20β300 K. MΓΆssbauer spectra were analyzed in terms of a model which takes into account the local environment of Fe atoms on three crystallographic sites (8f, 8j and 8i) and an influence of the random distribution of titanium on the 8i site. The 14 sextets with different intensities have been considered. The temperature dependencies of hyperfine interaction parameters and subspectra contributions were derived from experimental spectra. The hyperfine fields and the isomer shift increasing upon hydrogenation are discussed in terms of the hydrogen-induced Wigner-Seitz unit cell expansion and the s-electrons transfer from Fe atoms to the adjacent hydrogen atoms
- β¦